Acceleron Pharma Inc.
Transforming growth factor beta receptor type II fusion polypeptides

Abstract:

In certain aspects, the present disclosure relates to T.beta.RII fusion polypeptides comprising a heterologous portion and a truncated, ligand-binding portion of the extracellular domain of T.beta.RII polypeptide useful to selectively antagonize a T.beta.RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF.beta. associated disorders.